Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Catalina Valencia J.D. | President & Director | 187.5k | -- | 1949 |
| Mr. Robert T. Malasek | CFO & Secretary | 90k | -- | 1968 |
| Mr. Kurt Phinney | Chief Operating Officer | -- | -- | 1973 |
| Dr. Sergei A. Svarovsky M.B.A., Ph.D. | Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc. | -- | -- | -- |
| Dr. Douglas Lake Ph.D. | Chief Clinical Officer of Sapphire Biotech, Inc. | -- | -- | -- |
| Dr. Alim Seit-Nebi Ph.D. | CTO & Co-Founder of Sapphire Biotech, Inc. | -- | -- | -- |
| Mr. Jeffrey A. Busby | Senior Vice President of Business Development | -- | -- | -- |
| Dr. Joseph Tauber M.D. | Chief Medical Officer & Chairman of the Medical Advisory Board | -- | -- | 1957 |
| Dr. Maria J. Gonzalez Moa Ph.D. | Vice President of Product Development - Sapphire Biotech, Inc. | -- | -- | -- |
AXIM Biotechnologies, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 6
Description
AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Corporate Governance
Upcoming Events
April 14, 2025 at 8:00 PM UTC - April 18, 2025 at 8:00 PM UTC
AXIM Biotechnologies, Inc. Earnings Date
Recent Events
December 6, 2024 at 12:00 AM UTC
15-12G: Notice of termination of registration of a class of securities under Section 12(g)